October 2016, Vol 7, No 9

San Fransisco, CA—An economic model designed to determine the cost of instituting a clinical pathway inmetastatic colorectal cancer (mCRC) showed that the costs associated with implementing such a pathway may outweigh any potential cost-savings it may provide, at least for the near-term, according to Tanya G.K. Bentley, PhD, PHAR LLC, Beverly Hills, CA, and colleagues.